EA201591287A1 - Вакцины, содержащие стабилизированные тримеры оболочки вируса иммунодефицита человека, и способы их применения - Google Patents
Вакцины, содержащие стабилизированные тримеры оболочки вируса иммунодефицита человека, и способы их примененияInfo
- Publication number
- EA201591287A1 EA201591287A1 EA201591287A EA201591287A EA201591287A1 EA 201591287 A1 EA201591287 A1 EA 201591287A1 EA 201591287 A EA201591287 A EA 201591287A EA 201591287 A EA201591287 A EA 201591287A EA 201591287 A1 EA201591287 A1 EA 201591287A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- virus
- methods
- human immunodeficiency
- trimmers
- vaccines containing
- Prior art date
Links
- 241000725303 Human immunodeficiency virus Species 0.000 title abstract 5
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 239000013638 trimer Substances 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
- C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Изобретение относится к стабилизированным тримерам оболочки (Env) вируса иммунодефицита человека (ВИЧ). Изобретение также относится к вакцинам, нуклеиновым кислотам и векторам для доставки и/или обеспечения продукции стабилизированных тримеров Env ВИЧ. Кроме того, изобретение относится к способам получения и применения стабилизированных тримеров Env ВИЧ согласно изобретению в качестве вакцин.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361749737P | 2013-01-07 | 2013-01-07 | |
PCT/US2014/010543 WO2014107744A1 (en) | 2013-01-07 | 2014-01-07 | Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201591287A1 true EA201591287A1 (ru) | 2015-12-30 |
EA030983B1 EA030983B1 (ru) | 2018-10-31 |
Family
ID=51062514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201591287A EA030983B1 (ru) | 2013-01-07 | 2014-01-07 | ВАКЦИНЫ, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЕ ТРИМЕРЫ ОБОЛОЧКИ (Env) ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА (ВИЧ), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
Country Status (18)
Country | Link |
---|---|
US (4) | US9932370B2 (ru) |
EP (1) | EP2983686B1 (ru) |
JP (1) | JP6357487B2 (ru) |
KR (1) | KR102020758B1 (ru) |
CN (1) | CN105263506B (ru) |
AP (1) | AP2015008634A0 (ru) |
AU (2) | AU2014203886B2 (ru) |
CA (1) | CA2897059C (ru) |
EA (1) | EA030983B1 (ru) |
HK (1) | HK1214509A1 (ru) |
IL (1) | IL239805A (ru) |
MX (1) | MX2015008815A (ru) |
MY (1) | MY187152A (ru) |
NZ (1) | NZ710727A (ru) |
PH (1) | PH12015501526A1 (ru) |
SG (2) | SG11201505229XA (ru) |
WO (1) | WO2014107744A1 (ru) |
ZA (1) | ZA201505608B (ru) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9090673B2 (en) | 2003-12-12 | 2015-07-28 | City Of Hope | Synthetic conjugate of CpG DNA and T-help/CTL peptide |
TR201802130T4 (tr) * | 2008-10-10 | 2018-03-21 | Beth Israel Deaconess Medical Ct Inc | Biyokimyasal olarak stabilize edilmiş HIV-1 env trimer aşısı. |
AU2014203886B2 (en) | 2013-01-07 | 2017-11-02 | Beth Israel Deaconess Medical Center, Inc. | Stabilized human immunodeficiency virus (HIV) envelope (Env) trimer vaccines and methods of using the same |
WO2015048770A2 (en) | 2013-09-30 | 2015-04-02 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
EP3052518B1 (en) | 2013-10-04 | 2020-01-08 | Beth Israel Deaconess Medical Center, Inc. | Stabilized human immunodeficiency virus (hiv) clade c envelope (env) trimer vaccines and methods of using same |
US9750801B2 (en) * | 2014-02-28 | 2017-09-05 | Janssen Vaccines & Prevention B.V. | Replicating recombinant adenovirus vectors, compositions, and methods of use thereof |
TWI733652B (zh) | 2014-07-11 | 2021-07-21 | 美商基利科學股份有限公司 | 用於治療HIV之toll樣受體調節劑 |
PT3197489T (pt) * | 2014-09-26 | 2021-04-30 | Beth Israel Deaconess Medical Ct Inc | Métodos e composições para induzir a imunidade protetora contra a infeção pelo vírus da imunodeficiência humana |
MA40783A (fr) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
EP3240559A1 (en) * | 2014-12-24 | 2017-11-08 | Duke University | Compositions comprising ch505 envelopes, and trimers (eight valent hiv-1 composition and methods) |
WO2016196471A1 (en) | 2015-06-02 | 2016-12-08 | Cooper Human Systems Llc | Methods and compositions for treatment of hiv infection |
CN108368157B (zh) | 2015-12-15 | 2022-04-15 | 扬森疫苗与预防公司 | 人类免疫缺陷病毒抗原、载体、组合物、及其使用方法 |
WO2017156170A1 (en) * | 2016-03-09 | 2017-09-14 | University Of Massachusetts | Use of modified hiv-1 for generating fully human antibodies |
AU2017259275C1 (en) | 2016-05-02 | 2022-01-27 | The Scripps Research Institute | Compositions and methods related to HIV-1 immunogens |
JP6595132B2 (ja) | 2016-06-16 | 2019-10-23 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Hivワクチン製剤 |
WO2018045267A1 (en) | 2016-09-02 | 2018-03-08 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
CA3036959A1 (en) | 2016-09-15 | 2018-03-22 | Janssen Vaccines & Prevention B.V. | Trimer stabilizing hiv envelope protein mutations |
US11230572B2 (en) | 2016-10-17 | 2022-01-25 | Beth Israel Deaconess Medical Center, Inc. | Signature-based human immunodeficiency virus (HIV) envelope (Env) trimer vaccines and methods of using the same |
JP7272965B2 (ja) | 2017-06-15 | 2023-05-12 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Hiv抗原をコードするポックスウイルスベクターおよびその使用方法 |
CN110891601A (zh) | 2017-07-19 | 2020-03-17 | 扬森疫苗与预防公司 | 三聚体稳定性hiv包膜蛋白突变 |
US20190022212A1 (en) | 2017-07-21 | 2019-01-24 | Beth Israel Deaconess Medical Center, Inc. | Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human |
WO2019055888A1 (en) | 2017-09-18 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | METHODS OF INDUCING AN IMMUNE RESPONSE AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN SUBJECTS UNDER ANTIRETROVIRAL TREATMENT |
CN111542534B (zh) | 2017-11-01 | 2024-04-30 | 斯克利普斯研究院 | 新型支架式hiv-1疫苗免疫原 |
WO2019226829A1 (en) | 2018-05-22 | 2019-11-28 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
CA3103460A1 (en) | 2018-06-13 | 2019-12-19 | The Scripps Research Institute | Nanoparticle vaccines with novel structural components |
WO2020064621A1 (en) | 2018-09-25 | 2020-04-02 | Janssen Vaccines & Prevention B.V. | Method of inducing an immune response against human immunodeficiency virus by co-localized administration of vaccine components |
WO2020237052A1 (en) | 2019-05-22 | 2020-11-26 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
BR112022007929A2 (pt) | 2019-11-07 | 2022-07-12 | Janssen Vaccines & Prevention Bv | Purificação de proteínas |
WO2021146272A1 (en) * | 2020-01-13 | 2021-07-22 | The Regents Of The University Of California | Methods for treating viral infections |
WO2022005214A1 (ko) * | 2020-06-30 | 2022-01-06 | 포항공과대학교 산학협력단 | 코로나-19 바이러스의 스파이크 단백질의 에스터가수분해효소 활성을 이용한 코로나 바이러스 감염증 치료제 스크리닝 키트 및 상기 키트를 이용하여 스크리닝된 물질의 코로나 바이러스 감염증의 예방, 개선 또는 치료 용도 |
WO2023198815A1 (en) | 2022-04-14 | 2023-10-19 | Janssen Vaccines & Prevention B.V. | Sequential administration of adenoviruses |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US5298416A (en) | 1989-01-18 | 1994-03-29 | British Technology Group Ltd. | Attenuated polioviruses |
KR100242671B1 (ko) | 1991-03-07 | 2000-03-02 | 고돈 에릭 | 유전학적으로 처리한 백신 균주 |
US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
US6710173B1 (en) * | 1999-06-25 | 2004-03-23 | Progenics Pharmaceuticals, Inc. | Stabilized viral envelope proteins and uses thereof |
CA2384271A1 (en) | 1999-09-17 | 2001-03-22 | Joseph G. Sodroski | Stabilized soluble glycoprotein trimers |
WO2004044155A2 (en) | 2002-11-07 | 2004-05-27 | Beth Israel Deaconess Medical Center | MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE |
CA2505583C (en) | 2002-12-03 | 2014-07-15 | University Of Massachusetts | Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods |
WO2005052119A2 (en) | 2003-11-19 | 2005-06-09 | Beth Israel Deaconess Medical Center | Adjuvants of immune response |
WO2006002079A2 (en) | 2004-06-15 | 2006-01-05 | Progenics Pharmaceuticals, Inc. | Hiv-1 neutralizing antibodies elicited by trimeric hiv-1 envelope glycoprotein complex |
WO2006020071A2 (en) | 2004-07-16 | 2006-02-23 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Vaccines against aids comprising cmv/r-nucleic acid constructs |
CA2583843C (en) | 2004-10-13 | 2010-09-21 | Crucell Holland B.V. | Improved adenoviral vectors and uses thereof |
US20100221241A1 (en) | 2005-07-06 | 2010-09-02 | University Of Maryland Biotechnology Institute | Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites |
US8119140B2 (en) | 2005-08-23 | 2012-02-21 | Los Alamos Security, LLC | Immunogenic compositions comprising human immunodeficiency virus (HIV) mosaic Nef proteins |
WO2007104792A2 (en) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
WO2007149491A2 (en) | 2006-06-19 | 2007-12-27 | Progenics Pharmaceuticals, Inc. | Soluble stabilized trimeric hiv env proteins and uses thereof |
WO2008063331A2 (en) | 2006-10-23 | 2008-05-29 | Progenics Pharmaceuticals, Inc. | Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof |
TR201802130T4 (tr) * | 2008-10-10 | 2018-03-21 | Beth Israel Deaconess Medical Ct Inc | Biyokimyasal olarak stabilize edilmiş HIV-1 env trimer aşısı. |
HUE042397T2 (hu) | 2008-11-18 | 2019-06-28 | Beth Israel Deaconess Medical Ct Inc | Javított sejtes immunogenitású vírusellenes oltóanyagok |
EP2611465A4 (en) | 2010-08-31 | 2014-06-04 | Theraclone Sciences Inc | NEUTRALIZING ANTI-VIRUS ANTIBODIES FOR HUMAN IMMUNODEFICIENCY (HIV) |
WO2013036791A2 (en) | 2011-09-09 | 2013-03-14 | Beth Israel Deaconess Medical Center, Inc. | Modified adenoviral vectors and methods of treatment using same |
EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
WO2013055908A1 (en) | 2011-10-12 | 2013-04-18 | The Scripps Research Institute | An hiv-1 gp120 mini v3 loop and uses thereof |
US9683268B2 (en) | 2012-09-19 | 2017-06-20 | Beth Israel Deaconess | Viruses associated with immunodeficiency and enteropathy and methods using same |
WO2014078688A2 (en) | 2012-11-16 | 2014-05-22 | Beth Israel Deaconess Medical Center, Inc. | Recombinant adenoviruses and use thereof |
AU2014203886B2 (en) | 2013-01-07 | 2017-11-02 | Beth Israel Deaconess Medical Center, Inc. | Stabilized human immunodeficiency virus (HIV) envelope (Env) trimer vaccines and methods of using the same |
JP6594306B2 (ja) | 2013-07-08 | 2019-10-23 | ノバルティス アーゲー | キメラ表面タンパク質を有するロタウイルス粒子 |
TWI617156B (zh) | 2013-09-30 | 2018-03-01 | 高通公司 | 電力線通訊網路中的短封包通訊 |
WO2015048770A2 (en) | 2013-09-30 | 2015-04-02 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
EP3052518B1 (en) | 2013-10-04 | 2020-01-08 | Beth Israel Deaconess Medical Center, Inc. | Stabilized human immunodeficiency virus (hiv) clade c envelope (env) trimer vaccines and methods of using same |
-
2014
- 2014-01-07 AU AU2014203886A patent/AU2014203886B2/en not_active Expired - Fee Related
- 2014-01-07 CA CA2897059A patent/CA2897059C/en active Active
- 2014-01-07 SG SG11201505229XA patent/SG11201505229XA/en unknown
- 2014-01-07 MY MYPI2015702187A patent/MY187152A/en unknown
- 2014-01-07 CN CN201480012440.7A patent/CN105263506B/zh active Active
- 2014-01-07 EP EP14735323.9A patent/EP2983686B1/en active Active
- 2014-01-07 EA EA201591287A patent/EA030983B1/ru unknown
- 2014-01-07 MX MX2015008815A patent/MX2015008815A/es unknown
- 2014-01-07 KR KR1020157021492A patent/KR102020758B1/ko active IP Right Grant
- 2014-01-07 JP JP2015551842A patent/JP6357487B2/ja not_active Expired - Fee Related
- 2014-01-07 WO PCT/US2014/010543 patent/WO2014107744A1/en active Application Filing
- 2014-01-07 SG SG10201705880QA patent/SG10201705880QA/en unknown
- 2014-01-07 AP AP2015008634A patent/AP2015008634A0/xx unknown
- 2014-01-07 US US14/149,549 patent/US9932370B2/en active Active
- 2014-01-07 NZ NZ710727A patent/NZ710727A/en unknown
-
2015
- 2015-07-06 IL IL239805A patent/IL239805A/en active IP Right Grant
- 2015-07-06 PH PH12015501526A patent/PH12015501526A1/en unknown
- 2015-08-04 ZA ZA2015/05608A patent/ZA201505608B/en unknown
-
2016
- 2016-03-03 HK HK16102466.3A patent/HK1214509A1/zh unknown
-
2018
- 2018-01-30 AU AU2018200696A patent/AU2018200696B2/en active Active
- 2018-02-15 US US15/897,554 patent/US10160788B2/en active Active
- 2018-11-01 US US16/177,573 patent/US11059863B2/en active Active
-
2021
- 2021-06-23 US US17/304,557 patent/US20210317169A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201591287A1 (ru) | Вакцины, содержащие стабилизированные тримеры оболочки вируса иммунодефицита человека, и способы их применения | |
CY1124756T1 (el) | Εξουδετερωτικα αντισωματα του ιου ανθρωπινης ανοσοανεπαρκειας | |
MX2022006603A (es) | Vacuna contra el virus de la influenza de amplio espectro. | |
PH12018500855A1 (en) | Herpes simplex virus vaccine | |
MX2021006931A (es) | Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos. | |
EP4349404A3 (en) | Respiratory virus vaccines | |
EA201391515A1 (ru) | Инактивированная вакцина вируса денге | |
WO2015052543A3 (en) | Malaria vaccination | |
MX2018010483A (es) | Inmunogenos para vacunacion contra vih. | |
MA37749B1 (fr) | Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine | |
MX2015013304A (es) | Vacunas de nucleoproteina de la influenza. | |
IN2014DN09445A (ru) | ||
MX2019007924A (es) | Vacunas contra la influenza. | |
WO2015086738A3 (en) | Hiv vaccine | |
MX360137B (es) | Proteínas h5 del virus de la influenza h5n1 para usarse como un medicamento. | |
EA202191862A2 (ru) | Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения | |
TH173081A (th) | วัคซีนของไทรเมอร์ของถุงหุ้ม (Env) ของไวรัสโรคภูมิคุ้มกันบกพร่องของ มนุษย์ซึ่งทำให้เกิดเสถียรภาพ (HIV) และวิธีการของการใช้ที่เหมือนกัน | |
TH1501003876A (th) | วัคซีนของไทรเมอร์ของถุงหุ้ม (Env) ของไวรัสโรคภูมิคุ้มกันบกพร่องของ มนุษย์ซึ่งทำให้เกิดเสถียรภาพ (HIV) และวิธีการของการใช้ที่เหมือนกัน | |
PL410063A1 (pl) | Szczepionka, kompozycja farmaceutyczna, nośnik kwasów nukleinowych oraz innych substancji aktywnych biologicznie, zastosowanie kompozycji do wytwarzania szczepionki oraz zastosowanie kationowych pochodnych poliprenoli PTAI do wytwarzania substancji immunomodulujących |